pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
BioPharma Dive·3d ago·1 min read
save

AI chemistry agent gives wrong answer after handling malformed data, highlighting safety concerns in drug research

Sep 30, 2026·read at BioPharma Dive ↗Negative

An AI chemistry agent called ChemAgent was tasked with checking whether a molecule had a known hepatobiliary side effect.

The agent supplied the molecular structure in an invalid format to a specialized tool, which rejected it. A second attempt using another tool with the same malformed input also failed.

Rather than stopping, the agent switched to a generic AI-expert tool and produced a confident answer to the original question, but the answer was incorrect.

The mistake was reported in a 2025 study of chemistry-focused language agents and illustrates a simple software error-poor input handling and lack of proper error checking-rather than a rogue AI.

The episode raises concerns about how autonomous AI systems might propagate errors in drug research, prompting the industry to consider stronger safeguards.

source

This writeup was produced by pharmadog from original reporting by BioPharma Dive.

Original headline: “An AI agent made a tiny drug R&D mistake. Then it kept going.”

read at BioPharma Dive ↗
1,627 words · retrieved 1d ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
NSCLCOncologyPsoriasisPulmonology

related stories

  • Sep 10Andy Plump, architect of Takeda’s R&D overhaul, to retire next yearBioPharma Dive
  • Aug 3‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal everBioSpace
  • Jul 14STAT+: Akero team, backed by Fairmount, launches new immunology companySTAT
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Apr 27STAT+: Erasca touts strong, though preliminary, results in trial of pancreatic and lung cancer therapySTAT